Form 4: Dare Bioscience Director Susan L. Kelley Acquires Stock Options

Dare Bioscience Director Susan L. Kelley has acquired 4,500 stock options with an exercise price of $2.44, vesting based on service or a change in control.

Summary

• Susan L. Kelley, a Director of Dare Bioscience, Inc. (DARE), acquired 4,500 stock options.
• The options have an exercise price of $2.44 per share.
• The grant date for these options is July 9, 2025.
• The options expire on July 9, 2035.
• Vesting occurs on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, contingent on continued service as a director.
• The options will become fully exercisable upon a change in control of Dare Bioscience.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company and its shareholders.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service from the director, promoting stability in governance.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it primarily reports a standard equity grant to a director.

Risks

• No specific risks are detailed in this Form 4 filing, which is a transactional report.

Future Outlook

The stock options are subject to future vesting conditions, including continued service as a director for at least one year from the grant date or until the first annual stockholders' meeting, and full exercisability upon a change in control of the issuer.

Management Comments

• No direct management comments or quotes are provided in this transactional Form 4 filing.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, used to align executive and director incentives with shareholder value creation and to retain key talent.

Comparison to Industry Standards

• Specific comparisons to other companies' director compensation packages or project results are not provided within this Form 4 filing. The grant of stock options to directors is a standard industry practice for aligning interests.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• The acquisition of stock options by Susan L. Kelley, a Director of Dare Bioscience, Inc., represents a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: No direct impact on general employees is indicated.

Next Steps

• Vesting of the 4,500 stock options will occur on the earlier of July 9, 2026 (first anniversary of grant date) or immediately prior to Dare Bioscience's first annual meeting of stockholders occurring after the grant date, subject to continued service.
• The options will become fully exercisable upon a change in control of Dare Bioscience.

Key Dates

Keywords

Dare Bioscience, DARE, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Susan L. Kelley